Alcon Inc. (SWX:ALC)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 29.09B |
| Revenue (ttm) | 7.97B |
| Net Income (ttm) | 853.34M |
| Shares Out | 494.40M |
| EPS (ttm) | 1.72 |
| PE Ratio | 34.26 |
| Forward PE | 22.47 |
| Dividend | 0.28 (0.48%) |
| Ex-Dividend Date | May 13, 2025 |
| Volume | 64,107 |
| Average Volume | 973,570 |
| Open | 58.84 |
| Previous Close | 58.84 |
| Day's Range | 58.82 - 59.22 |
| 52-Week Range | 58.42 - 87.00 |
| Beta | 0.69 |
| RSI | 24.63 |
| Earnings Date | Nov 12, 2025 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ... [Read more]
Financial Performance
In 2024, Alcon's revenue was $9.91 billion, an increase of 4.82% compared to the previous year's $9.46 billion. Earnings were $1.02 billion, an increase of 4.52%.
Financial numbers in USD Financial StatementsNews
Merger Agreement Advances as Alcon (ALC) Clears 'Window Shop' Period
Merger Agreement Advances as Alcon (ALC) Clears 'Window Shop' Period
Yunqi Capital Opposes Staar Surgical (STAA) Sale to Alcon
Yunqi Capital Opposes Staar Surgical (STAA) Sale to Alcon
Yunqi Capital Rejects Alcon's Acquisition Proposal of STAAR Surgical (ALC)
Yunqi Capital Rejects Alcon's Acquisition Proposal of STAAR Surgical (ALC)
STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Major shareholder Yunqi Capital to vote against Staar Surgical 's proposed sale to Alcon
Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company's Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
HONG KONG--(BUSINESS WIRE)--Yunqi Capital Limited (together with its affiliates and the funds it advises, “Yunqi Capital”), an investment management firm and 5.1% shareholder of STAAR Surgical Company...
Is it a Prudent Move to Retain ALC Stock in Your Portfolio Now?
Alcon sees growth from surgical innovation and vision care products, but faces macro pressures and fierce competition.
Alcon's UNITY VCS Shows Superior Efficiency in Studies, Stock Up
ALC's UNITY VCS shows faster, more efficient cataract and vitreoretinal surgery results, lifting shares after study presentations.
Alcon (ALC) to Acquire Staar Surgical in $28 Per Share Cash Deal
Alcon (ALC) to Acquire Staar Surgical in $28 Per Share Cash Deal
Alcon (ALC) Boosts Surgical Efficiency with Unity Vitreoretinal Cataract System
Alcon (ALC) Boosts Surgical Efficiency with Unity Vitreoretinal Cataract System
STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, toda...
Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
GENEVA--(BUSINESS WIRE)--Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS.
Eye care giant Alcon acquires LumiThera, a Seattle-area startup behind device that treats vision loss
LumiThera's key innovation is a device for use by ophthalmologists that improves vision and slows its loss, with a focus on patients with dry age-related macular degeneration.
Alcon Inc. (ALC) Presents at Baird Global Healthcare Conference 2025 - Slideshow
Johnson Fistel Investigates Fairness of Proposed Sale of STAAR Surgical
SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP continues its investigation into whether the board members of STAAR Surgical Company (NASDAQ: STAA) breac...
Alcon Unveils Breakthrough Innovations at ESCRS Congress | ALC stock news
Alcon Unveils Breakthrough Innovations at ESCRS Congress | ALC stock news
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025 | ALC ...
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025 | ALC Stock News
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
GENEVA--(BUSINESS WIRE)--Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025.
Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
GENEVA--(BUSINESS WIRE)--Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025.
Broadwood Opposes Alcon's Acquisition Proposal for STAAR Surgical (STAA)
Broadwood Opposes Alcon's Acquisition Proposal for STAAR Surgical (STAA)
STAAR Surgical's largest holder to vote against Alcon bid
Alcon to Present at 2025 Baird Global Healthcare Conference
GENEVA--(BUSINESS WIRE)--Alcon to Present at 2025 Baird Global Healthcare Conference.
Alcon to Present at 2025 Baird Global Healthcare Conference
GENEVA--(BUSINESS WIRE)--Alcon to Present at 2025 Baird Global Healthcare Conference.
Trouble Ahead for Alcon Shares
Alcon Inc. (NYSE: ALC) is showing clear signs of weakness on its weekly chart. The stock has entered Phase 8 of its 18-phase Adhishthana cycle, and a critical breakdown from its Cakra formation has t...
Trouble Ahead for Alcon Shares
Alcon Inc. is showing clear signs of weakness on its weekly chart. The stock has entered Phase 8 of its 18-phase Adhishthana cycle, and a critical breakdown from its Cakra formation has triggered what...